Evidence guide

Retatrutide Dosage Research

Clinical trials studied defined Retatrutide dose arms under controlled protocols. Those arms describe research design, not instructions for unapproved vendor products.

Phase 2 design

The obesity trial evaluated weekly target-dose arms from 1 mg through 12 mg.

Titration was studied

Higher-dose groups used protocol-defined escalation to reduce gastrointestinal intolerance.

No approved label

Retatrutide remains investigational, so there is no FDA-approved consumer dosing schedule.

What the trial arms establish

The peer-reviewed Phase 2 obesity trial compared placebo with several target-dose and escalation groups over 48 weeks. It supports analysis of dose response and adverse events inside that protocol.

It does not establish that a vial sold by a research vendor is the trial product, nor does it validate self-directed use. Trial participants were screened, monitored, and supplied a controlled formulation.

What remains unresolved

The final commercial formulation and label have not been approved.
Research-vendor identity, concentration, sterility, and stability are not guaranteed by the trial publications.
Cross-trial dose comparisons with approved GLP-1 medicines are not equivalent to head-to-head evidence.